<DOC>
	<DOCNO>NCT02487225</DOCNO>
	<brief_summary>This single center randomize , double-blind , placebo-controlled study , conduct Mayo Clinic , Rochester , MN . The objective research determine whether inhibition tumor necrosis factor- alpha ( TNF-a ) pathway Pentoxifylline reduce inflammatory marker AP whether safe , beneficial well-tolerated patient acute pancreatitis AP . The study 2 group 75 patient , AP , randomly assign either drug placebo , look like drug , period 3 day time discharge , hospital discharge within 7 day admission . The level marker inflammation C-reactive protein ( C-RP ) , Interleukin-6 ( IL-6 ) , Interleukin-8 ( IL-8 ) Tumor Necrosis Factor-alpha ( TNF-a ) measure baseline 5 successive day time discharge , whichever occur early . Subjects adult patient =18 year older admit hospital within 72 hour diagnosis acute pancreatitis ( AP ) define least two follow : ( 1 ) amylase and/or lipase great 3x upper limit normal , ( 2 ) characteristic cross-sectional imaging , ( 3 ) typical abdominal pain . Enrollment study take place 24 hour admission . Determination group size base previous pilot study decrease important adverse outcome , provide dropout rate 10 % study . During 2012 , 263 patient AP admit institution , possess need infrastructure successful completion clinical drug intervention trial .</brief_summary>
	<brief_title>Pentoxifylline Treatment Acute Pancreatitis ( AP )</brief_title>
	<detailed_description>Participants put one two group ( randomize ) chance ( flip coin ) . This do neither participant investigator know group . Subject either treatment group ( Pentoxifylline medication ) control group ( Placebo ) . Placebo match pill medication . Participant take pill orally ( mouth ) start time admission enrollment . Participant receive total 9 dos three day hospitalization ( 72 hour ) . Research blood draw do measure baseline 5 successive day time discharge , whichever occur early . The research blood draw do time standard patient care blood draw , little extra ( 10 mL 2 teaspoon ) draw research . Information participant 's medical record gather hospitalize dismissal . The study continue gather clinical follow information 4 month follow hospitalization regard diagnosis acute pancreatitis .</detailed_description>
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Pancreatitis , Chronic</mesh_term>
	<mesh_term>Gallstones</mesh_term>
	<mesh_term>Pancreatitis , Alcoholic</mesh_term>
	<mesh_term>Pentoxifylline</mesh_term>
	<criteria>Inclusion criterion Enrollment within 72 hour diagnosis AP Ability give inform consent legal adult representative LAR able give inform consent subject need define buy LAR use guideline . Adult subject age â‰¥18 year . Moderate severe congestive heart failure , History seizure disorder demyelinate disease , Nursing mother , Pregnancy , History prior tuberculosis risk factor tuberculosis Evidence non corticosteroid immunosuppression ( malignancy , chronic renal failure , chemotherapy within 60 day , HIV ) Evidence active hemorrhage , Paralytic ileus severe nausea vomiting .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>